High Sensitive Troponin Assays sets new standards for cooperation between the Laboratory and the Cardiologists

Time: 11:00 - 11:40

Date: 24 April 2018

Theatre: Dodder B


Cardiac Troponins T (cTnT) and I (cTnI) are considered the gold standard diagnostic tests for the diagnosis of acute cardiac disease, superseding classical enzyme markers which lacked specificity. Following the advent of cTn assays in the early 1990’s and in response to the changing clinical need of the emergency room physician and the cardiologist; immunoassays for cTn have been redesigned with better low end precision allowing demonstrably high analytical sensitivity.

These high sensitivity assays allow two clinical milestones to be reached. Firstly, hs-cTn assays allow the identification of high and medium risk chest pain patients earlier than with contemporary sensitive assays and can be used within three hours or less to diagnose acute myocardial infarction. Speedy triage and diagnosis results in earlier treatment options such as percutaneous coronary intervention with the aim of preserving myocardial tissue function.

Secondly, the ability to detect cTn concentrations in an apparently healthy population may allow the use of cTn as a long term risk prediction marker rather than a humble event marker. This is true not only for the detection of sub-clinical acute cardiac pathology but in many other conditions where a secondary cardiac involvement is part of the clinical sequela. Both aspects of the clinical utility of hs-cTn will be discussed within this talk.


  • Dr David C. Gaze Lecturer in Clinical Biochemistry, Department of Biomedical Science, Faculty of Science and Technology - University of Westminster

« Back